3:39 PM
 | 
Mar 29, 2019
 |  BioCentury  |  Finance

ORI goes oncolytic

Why ORI is backing oncolytic virus company Cold Genesys

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer.

ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold Genesys Inc. since 2015 and was impressed by the company's data. Song decided to invest in the Santa Ana, Calif., company’s recent $22 million series C after founder Alex Yeung was replaced as CEO with Arthur Kuan in 2017, who had been COO.

Kuan is also a founding member of Hong...

Read the full 415 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >